Fundacion Arturo Lopez Perez
Providencia, Santiago Metropolitan, 7500921, Chile
Location status: Recruiting
Location contact
Christian Caglevic, md
CONTACT
Loreto Fernandez-Gonzalez, PhD(c)
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06501261
Patients with metastatic cancer experience multidimensional challenges that increase the risk of emotional distress, which must be addressed by the health team. Chile lacks evidence on effective therapeutic interventions in this population. CALM is a brief, individual (with the presence of a caregiver in one or more sessions) and evidence-based psychotherapy developed at The Princess Margaret Cancer Center. It consists of an intervention of 3 to 6 psychotherapy sessions over a period of 3 to 6 months. The Global CALM program aims to expand CALM research around the world, a program to which FALP has subscribed. Objective: To evaluate the preliminary efficacy of CALM in a sample of patients with metastatic cancer in Chile.
Phase 2 study of preliminary, pseudo-experimental efficacy, without a control group. The study will be carried out in Falp and Corporación Valientes.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Providencia, Santiago Metropolitan, 7500921, Chile
Location status: Recruiting
Christian Caglevic, md
CONTACT
Loreto Fernandez-Gonzalez, PhD(c)
PRINCIPAL_INVESTIGATOR
Patients with metastatic cancer experience multidimensional challenges that increase the risk of emotional distress, which must be addressed by the health team. Chile lacks evidence on effective therapeutic interventions in this population. CALM is a brief, individual (with the presence of a caregiver in one or more sessions) and evidence-based psychotherapy developed at The Princess Margaret Cancer Center. It consists of an intervention of 3 to 6 psychotherapy sessions over a period of 3 to 6 months. The Global CALM program aims to expand CALM research around the world, a program to which FALP has subscribed. Objective: To evaluate the preliminary efficacy of CALM in a sample of patients with metastatic cancer in Chile.
Phase 2 study of preliminary, pseudo-experimental efficacy, without a control group. The study will be carried out in Falp and Corporación Valientes.
Sample size 34 participants. Sessions will be online, 45 to 50 minutes long. Sessions can be recorded for supervision and training purposes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
psychotherapy sessions
Time frame: 3 months
Patient Health Questionnaire 9- Higher score means higher depression
Time frame: 6 months
Patient Health Questionnaire 9- Higher score means higher depression
Time frame: 3 months
Death and Dying Distress Scale- Higher score means higher depression
Time frame: 6 months
Death and Dying Distress Scale- Higher score means higher depression
Fundacion Arturo Lopez Perez
Other
Preliminary Efficacy and Acceptability of CALM Psychotherapy in Chile
Acronym: CALM-Ch
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04657068
Acinar Cell Carcinoma, Adenocarcinoma
Birmingham, Alabama, United States
View Trial DetailsNCT05267626
Adenocarcinoma, Advanced Solid Tumor
Miami, Florida, United States
View Trial DetailsNCT05245136
Characteristics Disease, Metastatic Cancer
Augsburg, Bavaria, Germany
View Trial DetailsNCT07043608
Adenocarcinoma, Bone Metastases of a Malignant Tumor
San Francisco, California, United States
View Trial Details